These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

788 related articles for article (PubMed ID: 26514204)

  • 1. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.
    Liu J; Clough SJ; Hutchinson AJ; Adamah-Biassi EB; Popovska-Gorevski M; Dubocovich ML
    Annu Rev Pharmacol Toxicol; 2016; 56():361-83. PubMed ID: 26514204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virtual discovery of melatonin receptor ligands to modulate circadian rhythms.
    Stein RM; Kang HJ; McCorvy JD; Glatfelter GC; Jones AJ; Che T; Slocum S; Huang XP; Savych O; Moroz YS; Stauch B; Johansson LC; Cherezov V; Kenakin T; Irwin JJ; Shoichet BK; Roth BL; Dubocovich ML
    Nature; 2020 Mar; 579(7800):609-614. PubMed ID: 32040955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melatonin MT
    Comai S; Lopez-Canul M; De Gregorio D; Posner A; Ettaoussi M; Guarnieri FC; Gobbi G
    Pharmacol Res; 2019 Jun; 144():343-356. PubMed ID: 31029764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential.
    Zlotos DP; Jockers R; Cecon E; Rivara S; Witt-Enderby PA
    J Med Chem; 2014 Apr; 57(8):3161-85. PubMed ID: 24228714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of melatonin receptors MT1 and MT2 in the hypothalamic suprachiasmatic nucleus during depression.
    Wu YH; Ursinus J; Zhou JN; Scheer FA; Ai-Min B; Jockers R; van Heerikhuize J; Swaab DF
    J Affect Disord; 2013 Jun; 148(2-3):357-67. PubMed ID: 23357659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis of the ligand binding and signaling mechanism of melatonin receptors.
    Wang Q; Lu Q; Guo Q; Teng M; Gong Q; Li X; Du Y; Liu Z; Tao Y
    Nat Commun; 2022 Jan; 13(1):454. PubMed ID: 35075127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. XFEL structures of the human MT
    Johansson LC; Stauch B; McCorvy JD; Han GW; Patel N; Huang XP; Batyuk A; Gati C; Slocum ST; Li C; Grandner JM; Hao S; Olsen RHJ; Tribo AR; Zaare S; Zhu L; Zatsepin NA; Weierstall U; Yous S; Stevens RC; Liu W; Roth BL; Katritch V; Cherezov V
    Nature; 2019 May; 569(7755):289-292. PubMed ID: 31019305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docking studies for melatonin receptors.
    Alkozi HA; Sánchez Montero JM; Doadrio AL; Pintor J
    Expert Opin Drug Discov; 2018 Mar; 13(3):241-248. PubMed ID: 29271261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melatonin receptors: role on sleep and circadian rhythm regulation.
    Dubocovich ML
    Sleep Med; 2007 Dec; 8 Suppl 3():34-42. PubMed ID: 18032103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional MT1 and MT2 melatonin receptors in mammals.
    Dubocovich ML; Markowska M
    Endocrine; 2005 Jul; 27(2):101-10. PubMed ID: 16217123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melatonin receptors, brain functions, and therapies.
    Oishi A; Gbahou F; Jockers R
    Handb Clin Neurol; 2021; 179():345-356. PubMed ID: 34225974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that membrane-bound G protein-coupled melatonin receptors MT1 and MT2 are not involved in the neuroprotective effects of melatonin in focal cerebral ischemia.
    Kilic U; Yilmaz B; Ugur M; Yüksel A; Reiter RJ; Hermann DM; Kilic E
    J Pineal Res; 2012 Mar; 52(2):228-35. PubMed ID: 21913972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melatonergic Receptors (Mt1/Mt2) as a Potential Additional Target of Novel Drugs for Depression.
    Boiko DI; Shkodina AD; Hasan MM; Bardhan M; Kazmi SK; Chopra H; Bhutra P; Baig AA; Skrypnikov AM
    Neurochem Res; 2022 Oct; 47(10):2909-2924. PubMed ID: 35689787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two indoleamines are secreted from rat pineal gland at night and act on melatonin receptors but are not night hormones.
    Lee BH; Bussi IL; de la Iglesia HO; Hague C; Koh DS; Hille B
    J Pineal Res; 2020 Mar; 68(2):e12622. PubMed ID: 31715643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melatonin receptors as therapeutic targets in the suprachiasmatic nucleus.
    Pévet P
    Expert Opin Ther Targets; 2016 Oct; 20(10):1209-18. PubMed ID: 27082492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology.
    Comai S; Gobbi G
    J Psychiatry Neurosci; 2014 Jan; 39(1):6-21. PubMed ID: 23971978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melatonin MT
    López-Canul M; Min SH; Posa L; De Gregorio D; Bedini A; Spadoni G; Gobbi G; Comai S
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31108968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the daily changes of melatonin receptors in the rat liver.
    Venegas C; García JA; Doerrier C; Volt H; Escames G; López LC; Reiter RJ; Acuña-Castroviejo D
    J Pineal Res; 2013 Apr; 54(3):313-21. PubMed ID: 23110416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and Validation of the First Family of Photo-Activatable Ligands for Melatonin Receptors.
    Somalo-Barranco G; Serra C; Lyons D; Piggins HD; Jockers R; Llebaria A
    J Med Chem; 2022 Aug; 65(16):11229-11240. PubMed ID: 35930058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New selective ligands of human cloned melatonin MT1 and MT2 receptors.
    Audinot V; Mailliet F; Lahaye-Brasseur C; Bonnaud A; Le Gall A; Amossé C; Dromaint S; Rodriguez M; Nagel N; Galizzi JP; Malpaux B; Guillaumet G; Lesieur D; Lefoulon F; Renard P; Delagrange P; Boutin JA
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Jun; 367(6):553-61. PubMed ID: 12764576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.